We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Findings from three real-world evidence clinical studies supported by AstraZeneca have indicated the need for better secondary prevention of long-term ischemic risk in people who have survived a heart attack.